

Big Idea
CONNECTpreneur

**VIRTUAL ROCKET
PITCH + POWER
NETWORKING**

**25
JULY
11AM - 1PM EDT**

CONNECTPRENEUR.ORG

AGENDA

11:00 - 11:05 AM

VIRTUAL NETWORKING

11:05 - 11:15 AM

WELCOME & INTRODUCTIONS

- TIEN WONG, Founder and Host, CONNECTpreneur Community
- SKYLAR RALLISON, Community Manager, CONNECTpreneur

11:15 - 12:00 PM

ROCKET PITCH SESSION

Companies will be introduced by:

- SARA CLASPER, Associate Attorney, NEXT powered by Shulman Rogers
- MARK HAAS, CEO, AEG

12:00 - 1:00 PM

PRESENTING COMPANY BREAKOUT ROOMS & VIRTUAL NETWORKING

PRESENTING COMPANIES



Alphyn Biologics, Inc. - Neal Koller



Couplet Care - Stacie McEntyre

FINALYTICS.AI

Finalytics.ai - Craig McLaughlin



Hedonia USA - Gary Schwartz



INTERACTOMEBIO

Interactome Bio - Adam Koster



ODYSSEY

Odyssey Wellness - Scott Frohman



PloomSocial - Cary Carlton



Transradial Technologies - Randy Hubbell



U-Credit - Kevin McNulty

SPEAKERS



TIEN WONG, CEO, OPUS8, INC. @tienwong

Tien is CEO of Opus8, an investment and advisory firm which helps technology companies and alternative investment fund managers raise capital. He is also Chairman of Lumious, a leader in corporate tech training and learning analytics, as well as Chairman of Lore Systems, a provider of network engineering, cloud computing, and strategic IT consulting.

In 1991, Tien co-founded and served as CEO of CyberRep, Inc. until its acquisition in 2003 by Affiliated Computer Services. CyberRep was one of the largest CRM outsourcing companies in the world with over 2,300 employees and \$80 million in revenue. Today, the CyberRep/ACS business unit is one of the world's largest call center operations, with nearly \$3 billion in revenue as divisions of Xerox, Conduent, and Continuum. CyberRep was ranked for 4 consecutive years in INC. Magazine's "Inc. 500" as one of the fastest-growing companies in the USA. CyberRep was profitable for 11 straight years and was backed by Allied Capital Corporation.

Tien is a recognized international expert in CRM, direct marketing, and BPO, having presented at dozens of industry events around the world on CRM and BPO topics. He has provided industry commentary on the ABC, Fox, NBC, CNBC, Maryland Public Television, and China's CCTV networks, as well as Time Magazine, The Washington Post, Inc. Magazine, and Success Magazine. He serves on several boards including the Montgomery County (MD) Economic Development Corp., Center for Innovation Technology GAP Fund's Investment Advisory Board, Junior Achievement, and Refraction. He was appointed by Governor Martin O'Malley to the 9-member Maryland Venture Fund Authority which allocates and manages over \$130 million of capital which is invested into top-tier venture funds and startups. He is an Entrepreneur in Residence at Georgetown University's McDonough School of Business, and a graduate of Dartmouth College.



SKYLAR RALLISON, COMMUNITY MANAGER, CONNECTPRENEUR

Skylar Rallison is a dynamic professional who wears multiple hats as the Community Manager for CONNECTpreneur and Business Analyst for Opus8. She graduated from The Marriott School of Business at Brigham Young University with a degree in Entrepreneurial Management. She has many years of experience in Business Management, Social Media Marketing/Management, Data Analytics, Business Leadership, and Project Management. With a diverse skill set and a passion for facilitating connections and driving business growth, Skylar thrives in the intersection of Community Management and Strategic Analysis.

Skylar enjoys her current role at CONNECTpreneur, which hosts the world's largest monthly investor pitch events as well as 1/2-day Forums with upwards of 900 RSVPs, featuring VIP guests, speakers, exciting presenting companies, and the best CXO to CXO networking on the East Coast. Skylar is pivotal in fostering engagement and building relationships within the investor and entrepreneur community. She creates inclusive digital spaces where members can share insights, collaborate on opportunities, and build a supportive network. Her role includes but is not limited to, team management, event coordination, project management, and marketing.

She also enjoys her current role as a business analyst at Opus8. Opus8 assists companies and fund managers (private equity, VC, and hedge funds) raise private capital from family offices, UHNW individuals, and institutions. Skylar leverages her analytical mindset and attention to detail to provide valuable insights for Opus8. Through her meticulous analysis of investment opportunities and industry research, Skylar helps drive informed decision-making, enabling Opus8 to curate high-quality events that bring together investors and promising ventures.



Alphyn Executive Summary

Breakthrough Drug of Choice for Atopic Dermatitis (Eczema)

Multi-Target Therapeutics™
A New Class of Drugs
More Powerful Therapeutics

MANAGEMENT TEAM

Neal Koller – Chairman & CEO
President & CEO, Board of Directors, life science businesses, **last exit at 16x**; Sr. Exec. Wyeth

Steven Pentelink – President
P&G Exec. managed **\$1B early tech portfolio**, global manager \$750M Beauty Care Products

Gary Pekoe, PhD – Chief Scientific Officer
Director for several multinational pharma companies, led development & approval of 1st & market leading topical antibiotic **Bactroban®**, lead clinical trial protocol writer for **Keytruda®**, 20 years clinical and regulatory adviser to pharma

Jazmyne Mink – Regulatory Affairs Manager
8 years' experience with Alphyn's AB-101

OPERATIONAL PARTNERS

Eagle Analytic - Analytics Lab
Emery Pharma - Chemistry & Microbiology Lab
World Class Ethnobotanist
World Class Botanical Chemistry & Analytics Lab
DDL - Formulation and Manufacture
PCCA - Formulation and Manufacture
Multiple Geo-local Agri Partners
TagOne - Supply Chain Management
Accelagen - Regulatory and Clinical Trials (AUS)
Symbio - Regulatory and Clinical Trials (US, EU)
DLA Piper - IP and Legal Worldwide
EisnerAmper - Finance and Tax (US)
Artus GmbH - Finance and Tax (EU)
RDI Partners - Finance and Tax (Australia)

SCIENCE ADVISORS

12 Global KOL Dermatologists

Dennis P. West, PhD
Prof Emer, Derm, Feinberg Sch of Med, Northwestern Univ

Peter Coderre
FDA IND & NDA Microbiology Reviewer (retired)
Scientific Advisory Board, CARB-X (BARDA, NIAID, NIH)
Antimicrobial Regulatory Consulting LLC

Patric Lundberg, PhD
Past Associate Prof, Microbiology/Molecular Cell Biology
Eastern Virginia Medical School

Shekhar Mitra, PhD
Sr VP, Global Innovation, Procter & Gamble (retired)
President, InnoPreneur, LLC

FUNDING TO DATE

Founders \$ 870 K (not capitalized)
Seed \$ 1.1 M (Convertible Note)
Pre-equity \$ 2.5 M (Convertible Note)
Series A \$ 5.5 M (Series A)
Non-dilutive \$ 1.9 M

FINANCING OPEN & MILESTONES

Series B \$18.0 M; **\$7M raised**
Lead Investor in place, diligence available

Complete Phase 2b AD Infected Trial - **FUNDED**
Complete 4x increase drug raw material - **FUNDED**
Complete Phase 2b AD Standard Trial
Complete 2nd drug Phase 2 Trial (EB - Orphan Drug)

COMPANY OVERVIEW


Alphyn is using its zabalafin (AB-101) drug platform to develop dermatological therapeutics with fewer side effects, greater patient tolerability and that are more effective, initially for Atopic Dermatitis (AD), and following for Epidermolysis Bullosa (EB). Zabalafin is a new class of drugs named Multi-Target Therapeutics™ providing unique multiple mechanisms of action from multiple bioactive compounds for multiple ways to treat an individual disease, to be more effective, and multiple diseases that can be treated. After only 3½ years of operation Alphyn's 1st drug candidate, topical zabalafin hydrogel, completed 2 Phase 2a clinical trials in AD confirming faster path to regulatory approval in the huge AD commercial opportunity. Clinical results better than competitive drugs point to "drug of choice" for this vast \$118 Billion market ⁵ with potential 800 million patient population ¹.

THE PROBLEMS IN TREATING AD

- 60.5% of adults report severe itch
- 67% of children and 33% of adults report significant sleep disturbances, poor quality of life ²
- 55 % report inadequate disease control ²
- 8.3-year life reduction with hospitalizations primarily due to AD bacteria-associated problems ³

TWO SUCCESSFUL PHASE 2a CLINICAL TRIALS: ZABALAFIN ADVANTAGES

- Most important - itch superior to competition
- Only AD drug to directly treat itch and the critical Bacteria Component of AD
- 90% of patients report significant improvement in Quality of Life
- 35% better reduction in inflammation versus dominate market leader (IGA)
- Side effect reduction and patient tolerability superior to competition
- Strong safety data resulted in: Waiver of Phase 1 clinical trial; Phase 2 clinical trials start age 2
- Clinical results point to 'Drug of Choice' for AD



MULTIPLE MARKET PROTECTION STRATEGIES

- Patent exclusivity potential to 2042: US & Worldwide, Composition of Matter, Methods of Use
- Regulatory exclusivity possible: 10 years USA, 8 years Europe & Japan
- No FDA generic drug competition possibility
- Estimated 15 year robust drug raw material supply protection: Quantity, Contracts, Regulatory

VAST AND GROWING AD MARKET

Drug (Company)	Time on Market	Annualized Sales ⁴	Estimated Patient # ⁵
Dupixent® (Sanofi)	4 years	\$7 Billion	~ 270,000
Opzelura® (Incyte)	2 years	\$380 Million	~ 103,500

AD STRONG COMPARABLE EXIT DEALS

Acquired / Licensed	When	Exit: Cash plus Milestones	Exit Stage
Proteologix (by J&J)	May '24	\$850 Million + Milestones	Pre-clinical
Kyowa Kirin (by Amgen)	Jun '21	\$1.25 Billion	Phase 2 clinical trial
Kymab (by Sanofi)	Jan '21	\$1.45 Billion	Phase 2 clinical trial

Company Overview: Couplet Care, Inc. is transforming the postnatal experience in hospitals and birthing centers with an innovative medical infant bassinet – a University of North Carolina spin-out, 510(k) Exempt, Class II Medical Device, with patents in 7 countries, exclusive IP, strong interest from hospitals, and will be for sale in the US Q3 '24.

Problem: The global standard on postnatal units is “rooming-in” – an infant remains in the hospital room with the mom – leading to long-term positive health outcomes. But outdated bassinets are barriers to accessing the infant, leading to infant drops/injuries, infant suffocation, maternal pain and distress, an inability to establish breastfeeding, nursing inefficiencies, and hospital risk at a time that should be joyful for all.

Solution: **Couplet Care Bassinet™** is the ONLY bassinet that allows the mom to 100% independently access and transfer the infant without the need of a second person. Extensive research and user-need surveys informed the design to achieve infant safety, maternal access and comfort, and nursing efficiency.

Couplet Care, Inc.

www.coupletcare.com

Stacie@CoupletCare.com

(919) 597-0296

Funding

Total seeking: \$750K Convertible Note Bridge Round: Remaining \$350k Series A - \$2 million Q1 '25

Total raised to date:

\$2.5M non-dilutive funding (NIH+)
\$1.4M investments

Financials

Revenue: Pre-revenue

Cash Flow in 2025

Team

CEO: Stacie McEntyre, 35 years in healthcare, visioned, built and led a \$65M healthcare system.

Founder: Dr. Kristin Tully, internationally recognized University of North Carolina maternal-infant health & safety expert

Board of Directors: Don Holzworth, Chair; Jan Davis; Nikin Shah

Board of Advisors: Dr. Carl Seashore, Dr. Andrea Braden, Ty Hagler

Conclusion: Hospitals must update equipment to reduce risks. We have a clear commercialization pathway leading to a strong return for investors. while transforming lives.

Technology: Couplet Care Bassinet™ was designed by Dr. Kristin Tully, maternal infant expert at the University of NC, and was backed with extensive research - **8 published peer-reviewed scientific articles** authored by Dr. Tully supporting the development of the Couplet Care Bassinet, and with research by Drs. Alison Stuebe, Carl Seashore, and Catherine Sullivan with the **Carolina Global Breastfeeding Institute**. Input from 3,500 new moms and healthcare workers to address the serious gap between the benefits of “rooming-in” and the detriments of old-style bassinets. Couplet Care’s NIH usability pilot study showed statistical significance in nursing efficiency, with a 73% reduction in mom calls to the nurse for non-medical reason - meaningful in today’s environment of healthcare staffing shortages.

IP/Defensibility: Couplet Care, Inc. holds the IP in an exclusive license agreement with the UNC Department of Technology Commercialization. Freedom to Operate work is completed. Patents in 7 countries. Continuation claims & new patent claims filed 3Q23.

Competition/Competitive Advantage: The Couplet Care Bassinet™ uniquely allows the mom to **100% independently access** the infant. Standard bassinet, the Stryker Nara, and the Halo Bassinet© are common competitive models, but don’t offer full **independent access**.

Market Size/Customers: \$1.4B Total Addressable Market (2019 OECD International Healthcare Statistics). Target customers include women’s hospitals and birthing centers, initially in the US, but ultimately in 6 EU, Canada, Japan, China, Brazil, and Australia and beyond.

Business Model: \$4500 - 6,000 projected MSRP; ~50 - 60% margins expected at scale in 2026. Revenue through hospital Operations/CAPEX budgets, grants, auxiliary funds, or lease financing programs.

Traction: NIH Phase II Study being conducted at Johns Hopkins University. Will be “for sale in the US” by Q3 '24. Pre-production units are expected in 4Q24, with the first 600 production units delivered to hospitals beginning 2Q25.

FINALYTICS.AI

Value Proposition: *Finalytics.ai enables banks and credit unions to personalize the digital experience using AI to drive new customer acquisition, increase wallet share, and improve satisfaction.*

Company Background:

Finalytics.ai was founded in 2021, and has been self-funded to date, growing to over \$1.5m in ARR with 15 customers.

Leadership Team:

The senior management team at Finalytics.ai is comprised of seasoned digital banking veterans with decades of combined experience in banking:

*Craig McLaughlin: CEO & Co-founder, with 25 years of banking experience.
Mark Ryan: CAO & Co-founder, with 25 years of banking data experience.
John McKenna: VP of Sales, with 31 years of banking sale experience.
Scott Barnard: CTO, with 20 years of development and UX experience.
Baron Conway: Chief Strategy Officer, with 25 years digital finance experience.*

Products/Services:

Finalytics.ai is our flagship product – a SaaS platform. It delivers a holistic customer experience bridging the gap across online banking, CRM, and online account origination systems, enabling ‘Segment-of-One’ personalized experiences across all digital channels for banks.

Technologies/Special Know-How:

We know banking and have deep expertise in data analytics. Our experience is in solving the challenges community banks face in navigating digital transformation. We recognized the market whitespace for personalization and set out to fill it, deliver truly omni-channel customer experiences.

Market:

Our market is initially the 5000 banks and 5000 credit unions in North America. In the medium term we will expand to insurance and investment services.

Distribution Channels:

We sell direct and through partners.

Competition:

We compete against a series of technology competitors. Our strength is two pronged: (1) Industry specialization/integrations and (2) Speed to deployment with integration built into the offering.

Financial Projections (Unaudited):

	2022	2023	2024	2025	2026
Revenue	300,000	1,324,908	\$ 3,000,000.00	\$4,500,000	\$6,000,000
EBIT	(1,295,033.00)	(19,485.00)			

Quick Facts

Company Name: Finalytics.ai

CEO: Craig McLaughlin

Address:

**1825 S. Grant St
San Mateo CA 94402**

Phone: 415-806-3820

Email: craig@finalytics.ai

Website: www.finalytics.ai

Industry: Financial Services

Domain: Banking

Bank: Chase

Law Firm: Mannat

Patent Estate:

Number of Employees: 12

Amount of Financing Sought:
\$5m

Current Investors:
Bootstrapped

Use of Funds: Product development and sales/marketing.

Auditor: TBD

EXECUTIVE SUMMARY




VALUE PROPOSITION

Hedonia is a revolutionary product, an all-natural, first-of-its-kind medical food. It is specially formulated to address the unique nutritional needs of people suffering from depression, without the need for a prescription and without the side effect profile associated with pharmacological agents.

Hedonia™ is not a drug. It is not a supplement. It is a unique patented 3-in-1 product classified as a medical food. Hedonia is specifically formulated to address the unique nutritional imbalances and or deficiencies of people with depression, which cannot be managed by an ordinary diet alone. The nutrients (Omega-3, SAMe,

and L-methylfolate) occur naturally in your body but may be out of balance in your brain if you suffer from depression. Hedonia works by raising the levels of these critical nutrients to normal, healthy levels. Medical foods have been used since the 1950s. They have been developed for many diseases, such as Crohn's, ulcerative colitis, gastroesophageal reflux, insomnia, Alzheimer's, and Parkinson's. Examples of Medical foods include Pedialyte, Ensure, Glucerna, and Pulmocare.



LEADERSHIP TEAM

Alexander Vuckovic, M.D. Founder,
Inventor & Chief Scientific Officer

Dany Sfeir, Chief Executive Officer

Bengt Persson, Chief Operating Officer

Shepard Kramer, Chief Marketing Officer

SCIENCE BOARD OF ADVISORS

Alexander Vuckovic, MD Founder & CSO

Dr. Joseph Firth, PhD University of Manchester

Derek Tobin, PhD Clinical Science Manger Epax Norway

Prof. Jerome Sarris, PhD Psycae Institute

COMPANY BACKGROUND

Hedonia USA, Inc. was incorporated in January 2021 in the State of Delaware. The company was founded by Dr. Alex Vuckovic, a Harvard Medical School Psychiatrist and Pscopharmacologist, based upon his over 40 years of treating patients with depression as well as substantial published research by many practitioners.

DISTRIBUTION CHANNELS

We intend to launch Hedonia in mid Q3 2024 and will initially be marketed as medical food and sold as direct to consumer (D2C) via our website. After the launch of the medical food product, we will market Hedonia selling to select retailers. Within 2 years we will execute our full retail strategy, working with pharmacies and large retailers to sell Hedonia both as a medical food and in alternate formulation with a family of supplements to address the 80 million USA residents who take supplements daily.

COMPETITION

There has never been a product like Hedonia on the market and as we sit here today there is no competition and will not be for a long time because of our patent protection.

PATENTS

Hedonia has patents that protect the product through 2037 both domestically and internationally as well as in an supplement version. In addition, the company has a patent on its special dual capsule delivery system.

ADDRESSABLE MARKET

The World Health Organization (WHO) estimates there are one billion people globally suffering from depression, or about 1 in every 5 people. In the United States, 31 million people have mild to intermittent depression. At an average cost of \$2,200 for a one-year supply of Hedonia would be a \$6.82 billion in market just in the USA.

ASK

Hedonia USA, Inc. has raised \$2.9 million to date both in seed capital and a Series A round. Currently, we are seeking \$10 million in Series B financing. The capital will be used as follows:

Marketing and Media	52%
Manufacturing and raw material	22%
Talent acquisition	11%
Research & development	15%
Total	100%

Industry: Biopharmaceuticals
IP/Patent Portfolio: 5 total assets
 (Bioprocess, Delivery, Targeting, Neurology, Cardiology)

Number of Employees: 7
Amount of Financing Sought: \$2.5M

Company Background:

Company founded on several decades of Extracellular Vesicle (EV) therapeutic research with focus in **Neurology, Cardiovascular and Aesthetic markets**. Over the last 5 years, we have developed proven superior EV and exosome products and advanced bioprocesses providing near-term and long-term value.

Value Proposition:

Next generation superior EV products and IP protected manufacturing bioprocess targeting the rapid growth and expansion of EV applications. Q3 2024 commercialization of IB's superior exosome products for the Aesthetics market. Strong regulatory property pipeline of FDA IND filings in Neurology and Cardiovascular via novel enzymatic glycolytic mediated RNA delivery via Extracellular Vesicles in Q4 2024.

Products/Services:

Our superior EV and Exosome products have been validated through *in vivo* studies and industry standard biomarkers. Our patented bioprocess is under development and prototype, with sourcing, isolation, purification, and characterization validated internally. Our platform resolves major challenges in the field including broad drug compatibility, immune silence, as well as rapid distribution and retention, expanding the therapeutic index.


Technologies:

Combining our IP-protected bioprocess with global clinician scientists to execute our in-licensed asset portfolio that is **scalable, reproducible, and circumvents current issues in the cell therapy domain limiting the success of preclinical and clinical readouts.**

Market:

Our initial target market will focus on the fast-growing aesthetic medical spas, plastic surgeons and dermatologists using our products to rejuvenate the skin – Cosmetic Serum (\$3B TAM). Additionally, our lead FDA program is focused on Neurology (\$6B TAM) and Cardiology (\$15B TAM) through our strong pipeline from our Henry Ford partnership and our RNA Therapeutics development option with Oxford.

IB Targeting the Exosome market growth driven by increasing clinical applications



 **Sales & Distribution:** We currently have converted customers for our regenerative dermatology products and **project \$3M+ sales in fiscal 2024-25, growing to \$10M+ in fiscal 2026-27.**

Financial Projections

(Unaudited)	2023	2024	2025	2026
Revenue	\$252,500	\$3,615,000	\$7,750,000	\$10,625,000
Net Income	-\$329,905	\$261,000	\$776,000	\$1,366,250

Capital Raise:

\$2.5M Seed funding to complete near term aesthetic product commercialization and manufacturing scale. 2-year funding to complete IND application in H1 2025.

Use of Funds:

Production/Operational Cost, Bioprocess prototype development, Master Control execution, production batch execution, product marketing, and IND regulatory fees.

Leadership Team:

Adam Koster,
CEO, Co-Founder

Matthew Peterson,
MD, MBA, Chief Medical Officer

Frederick Naftolin,
MD, PhD, Co-Founder

James Secrest,
MA, DC, Director of Manufacturing

Company Name: Interactome Biotherapeutics Inc

Location: 401 W Mosel Ave Kalamazoo, MI 49004

Bank: Chase Life Sciences Connect

Law Firm: Dykema Law

Contact: Adam Koster, CEO, Co-Founder

Phone: (773) 919-5430

Email: invest@interactomebio.com

Website: www.interactomebio.com


Medical & Scientific Advisory Board:

Michael Chopp, PhD
Chair, Henry Ford Neuro

Kenneth Witwer, PhD
ISEV President, John's Hopkins


Shawn Tierney, DC, RMSK
Nerve Hydrodissection Expert

Dhanu Gupta, PhD
Oxford University



ODYSSEY is a leader in the Natural Channel Ready-to-Drink (RTD) energy beverage market that specializes in cognitive and mood-boosting performance - disrupting the stagnant, outdated energy drink category by using an innovative proprietary blend of high potency Lion's Mane, Cordyceps, and other ingredients to develop these effects. We use no artificial sweeteners or preservatives and have exceptional flavor.

- Product Launch - June 2021
- 17.8M Fully Diluted LLC Units Prior to Ongoing Capital Raise at \$3 Per Convertible Unit
- Over \$18M Raised to Date
- 26 Employees
- HQ in Fort Lauderdale, FL



Annual Net Sales

2022	- \$2.1M
2023	- \$4.9M
2024E	- \$12M
2025E	- \$27M
2026E	- \$100M+



ODYSSEY

Our original product launched into the Natural Channel in January 2022. Only 85mg of caffeine with high potency Lion's Mane and Cordyceps, for cognitive and mood-boosting performance. This product has some of the highest velocities in the Natural beverage category.

- ODYSSEY is pioneering a new natural functional beverage category that delivers mental clarity, energy and hydration.
- ODYSSEY was presented 2024 VITY Award for best Functional Beverage in Sports Nutrition Category.
- Recently authorized to stock all ODESSEY product SKUs in all Target® stores nationwide.
- Recently authorized to stock all ODESSEY 222 SKUs in all 7 Eleven stores from Orlando to the Florida Keys as well as all Kroger grocery stores in Ohio.
- ODYSSEY ranked #1 in sales in Natural Channel by both INFRA and National Co-op Grocers (SPINS 12 week read ending 6/16/2024).
- Posted record Q2 2024 AMAZON sales (\$810K; up 246%) and AMAZON subscribers (3,189; up 276%).
- Mordor Intelligence estimates the Ready-to-Drink Beverages Market at \$361B in 2024 and is expected to reach \$456B by 2029 (4.8% CAGR).
- Target markets: Gen Z (18-24), Millennial (25-40), Gamers, Soccer Moms, Athletes and Golfers.



ODYSSEY 222

Ideal for MULO / Convenience Stores. It has 222mg of caffeine plus high potency Lion's Mane and Cordyceps. This gives sustainable energy and clarity over a longer period without the crash and jitters.

KEY DISTRIBUTORS Over 25 Nationwide



ODYSSEY REVIVE

Was formulated in mind for music festival goers and night life. Utilizing zero caffeine, with electrolytes, magnesium, zinc, vitamin C, and high potency Lion's Mane and Cordyceps. This functional product is winning throughout many channels.

KEY RETAILERS

Sold in Over 8,000 Stores Nationwide



Value Proposition: PloomSocial revolutionizes the fundraising experience by combining the power of video storytelling with the efficiency of a comprehensive, secure platform. Our unique approach provides several key benefits:

1. **Engagement Through Storytelling:** We enable fundraisers to create compelling, episodic video content that connects donors emotionally to their cause, fostering deeper engagement and long-term support.
2. **Transparency and Trust:** By offering real-time updates and showcasing the tangible impact of contributions, PloomSocial builds transparency and trust between fundraisers and donors.
3. **Ease of Use:** Our platform is designed for simplicity, allowing users to easily create campaigns, share them with their communities, and track progress. The intuitive interface ensures that anyone can navigate and use the platform effectively.
4. **Secure Transactions:** PloomSocial is fully KYC compliant and integrates robust AML features, ensuring that all transactions are secure. We utilize Stripe for seamless and reliable payment processing.

Company Background:

PloomSocial, founded by Cary Carlton and Chris Bobo in 2022, revolutionizes fundraising by merging video storytelling with social networking. Our platform enhances donor engagement and transparency, enabling fundraisers to connect directly with their communities. Serving a wide range of users, from nonprofits to personal campaigns, PloomSocial stands out by turning fundraising into a dynamic, impactful social experience.

Leadership Team:

1. Cary Carlton; 20+ years software sales leadership
2. Chris Bobo: 20+ years software sales leadership
3. Quan Tran: 20+ YEARS CTO leadership
4. Kevin Harrington: Advisory Board Member and Investor
5. Brandon T Adams: Advisory Board Member and Investor
6. Randy Lewis: Advisory Board, COO of REIT Mutual Fund- Founder

Products/Services:

1. Fully KYC compliant and AML-integrated platform
2. Episodic Video Storytelling
3. Ad Revenue Sharing, SAS Premium Services
4. Social Network Introducing- providing multiple donor windows
5. PloomSocial donates 0.5% of its platform revenue to our charitable partners.

Technologies/Special Know-How:

N/A

Market:

Non-Profit Organizations

Community and Educational Groups: Schools, sports teams, and local organizations

Individual Fundraisers: People raising money for personal causes, medical expenses
 PloomSocial operates on a transaction-based revenue model, charging an 8% percentage fee on each donation processed through our platform. We offer premium services and features for fundraisers who seek advanced tools and personalized support.
 TAM=265B/SAM=32b SOM=2.17B

Distribution Channels: N/A

Competition:

1. GoFundMe
2. GiveButter
3. Instagram
4. Facebook
5. Donor Box

Financial Projections (Unaudited):

	2024	2025	2026	2027	2028
Revenue	800,000	4,290,000	13,000,000	26,000,000	50,000,000
EBIT (dollars in thousands)	350,000	1,501,500	4,500,000	8,320,000	15,000,000

Quick Facts
Company Name: PloomSocial

Contact: Cary Carlton

**Address: 2211 Michelson Drive
 Irvine CA 92621
 Phone: 949-826-1321
 Email: cary@ploomsocial.com
 Website: ploomsocial.com**

Industry: FinTech

Domain:

Bank: Banc of California

Law Firm: Perkins & Coie

Patent Estate:

Number of Employees: 5

Leadership Team: 4

**Amount of Financing Sought:
 3,000,000**

Current Investors: 25

**Use of Funds: Technology
 enhancements. User traction.
 Brand Awareness**

Auditor: N/a

Executive Summary, July 2024

Value Proposition

The SĀPH device is a radial artery closure system that provides a unique method of creating hemostasis following a catheterization procedure. This patent-pending technology offers investors the opportunity to engage with a truly new standard of care in one of the fastest growing markets in the interventional cardiovascular space.

Company Background:

Transradial Technologies, Inc. is a medical device company focused on developing a novel, minimally invasive transradial vascular closure device. The device is designed to offer a “fast, safe, and easy-to-use” closure solution for radial artery punctures created during a full range of interventional procedures including cardiac catheterization, percutaneous coronary revascularization, and peripheral angiography/revascularization. Transradial Technologies, Inc. has worldwide and exclusive rights to the technology via an agreement with Transluminal Technologies, Inc.

Leadership Team: Five exits worth over \$1B – Multiple Acquisitions) & over 100+ years of medical technologies experience

Randy Hubbell, CEO – Over 30 years of medical device, biotechnology and pharmaceutical industry experience at both large multinationals, such as Boston Scientific Corporation and Johnson & Johnson, and four start-ups that led to three exits, including Cardiva Medical, a vascular closure company that was sold to Haemonetics for \$500M. Was CEO for Carmell Corp (NASDAQ: CTCX) from 2016 to 2023, a journey that started with a spin out of Carnegie Mellon University worth \$6M to a public merger at \$150M.

Ron Caputo, MD, CMO – Dr. Caputo is a practicing interventional cardiologist with over 80 authored/co-authored peer-reviewed publications and a history of successful medical device entrepreneurship, including co-founding Angiolink, Corp which was acquired by Medtronic (NYSE: MDT).

Stephen Green, President – Steve has over 40 years of medical device design and development that includes over 20 US and Int’l patents and multiple regulatory product approvals.

Quick Facts

Company Name:

Transradial Technologies, Inc.

Contact: Randy Hubbell

Address:

2930 E. Genesee St.
Syracuse, NY 13224

Phone: (215) 688-6196

Email:

Randolphhubbell@hubbellmedtech.com

Website: Under construction

Industry: Medical Device

Bank: Pinnacle

Law Firm: Jones Walker

Patent Estate: Patent Pending

Number of Employees: 4

Amount of Financing Sought: \$3M


Current Investors:

Transluminal Technologies, Inc.

Use of Funds: 510k registration, observational study, general & administrative

Product & Technology

SĀPH (Suction Activated Patent Hemostasis) – Designed to address the growing market of procedures performed using radial artery access, the SĀPH device uniquely closes the arterial puncture by expanding the artery to create compression with the artery puncture site and the surrounding tissue rather than the traditional method of compressing the artery with a tourniquet around the wrist. The SĀPH device achieves a lower rate of radial artery occlusion, a more comfortable patient experience, and importantly, reduces the workload for recovery staff, (i.e. no intermittent patient monitoring is necessary). First in man testing (17 patients) has been successfully completed. This technology is also well suited to transpedal and distal radial arterial access and potentially femoral venous procedures.



Intellectual Property

A non-provisional US patent application (August 2022) as well as a continuation-in-part has been filed with the USPTO. A full runway of patent life remains.

Distribution Channels

Expected sales channel through a large multi-national strategic **via acquisition** with existing sales & marketing infrastructure in this space.

Competition

The current standard of care, conventional compression, utilizes a tourniquet-band and inflatable bladder which compresses and flattens the wrist and artery, restricting blood flow, and creating significant discomfort for the patient. Terumo Corporation currently holds a predominant market share (>70%) in this conventional compression category. Many large companies, such as Boston Scientific, Medtronic, Abbott, Merit Medical and Teleflex have significant presence in the hospital where the procedures occur and have little or no radial access vascular closure sales.

Financial Projections (Unaudited)

In Millions	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036
Revenue	\$ 1.10	\$ 3.36	\$ 13.19	\$ 22.04	\$ 30.63	\$ 47.79	\$ 66.15	\$ 94.25	\$ 115.22	\$ 128.14	\$ 141.56



U-Credit

Shaping the future of carbon emissions reduction

A carbon offset is a reduction or removal of emissions of CO₂ or other greenhouse gases (GHGs) through a qualified project, typically representing an emission reduction of 1 metric ton of CO₂e. Carbon credits or offsets are purchased or traded by businesses or individuals to reduce their carbon intensity emissions.

Carbon Credit Market Concerns

For these markets to work the carbon reduction or offset projects need to be verified and certified to confirm that they meet established criteria, typically calling for manual field work and desk work to establish the credit. However, the current market faces concerns regarding verification and pricing due to the lack of a single governing standard.

The U-Credit Solution

U-Credit provides a solution by automating and simplifying the verification and certification process, ensuring the accuracy and integrity of the data in the process. Using advanced technology like smart contracts and distributed ledger systems, U-Credit tracks and verifies carbon emissions reductions in a tamper-proof manner. This improved legitimacy of the carbon offset increases its value while significantly reducing the cost of the current verification process. Tokenization then allows for easy purchase, sale, and trading of the U-Credits created.

Creating and Verifying Carbon Credits

With the help of AI algorithms, U-Credit can verify the creation of carbon credits by cross-referencing data from various sources such as geolocation, weather reports, usage patterns, system operations, emission permits, and market dynamics. Real-time monitoring allows for ongoing validation of the credits and reduces the need for human intervention in the verification and monitoring process.

Creating Immutable Data Sets

To ensure tamper-proof tracking of carbon emissions reductions and guarantee the integrity of transactions, a distributed ledger system adds an extra layer of security by creating an immutable record of the data stored. Transactions are kept secure and safe as they are verified and validated via the secure DLT platform.

Carbon Credit Tracking

The U-Credit system consists of user onboarding, smart meters, and a distributed ledger database, all working together to create an accountable and transparent history of carbon credit generation and consumption tied to energy generation.

Tokenizing Carbon Credits

Through the DLT, U-Credit tokens can be created to represent NFTs based on the metric tons of CO₂e created, the current standard. U-Credit tokens are minted based on data gathered by smart meters with proprietary hardware, or through the pre-sale of credits to fund carbon reductions projects.

Creation of Tradable Credits

The U-Credit tokens represent a store of value backed by the underlying carbon offsets. Thus, the tokens can be used in purchase, sale, or trade for other goods and services, or used as collateral. Once they are applied as an offset, however, the tokens are redeemed and effectively removed from circulation.

U-Credit Facilitates Carbon Reduction

U-Credit opens new opportunities for energy producers and consumers, allowing them to monetize carbon credits more easily. By reducing the cost for carbon credit creation and validation, U-Credit democratizes the carbon market and enables individuals to participate in creating and selling carbon credits, even using carbon credits for purchases of goods and services. U-Credit incentivizes sustainable energy practices resulting in cleaner and more efficient energy solutions and eco-friendly choices.

Transforming Energy Markets

U-Credit has the potential to revolutionize the energy market by creating a common basis between energy sources. Utilizing its Core Technology any sort of energy produced, whether electricity, gaseous fuels (e.g., natural gas, hydrogen), or liquid fuels (diesel, gasoline), can all be automatically converted to a carbon equivalent. Tying the various forms of energy to a carbon value can potentially put them on equal footing, thus providing a cross-reference of value, and allowing for purchase, sale, and trading across energy resources.

PARTNERS



NEXT powered by SHULMAN ROGERS

NEXT disrupts the legacy legal industry by offering a broad range of fixed fee solutions (stand-alone products and annual legal plans) delivered by senior attorneys with valuable business expertise. NEXT solves the problem that startup and emerging growth companies face when launching their business as well as scaling: lack of access to predictable legal fees, seasoned attorneys, the latest technology and key business services. We use cutting edge technology platforms to deliver real efficiencies, transparency and a collaborative environment for clients, attorneys and investors. NEXT partners with its clients to de-risk their business and get to the NEXT level, together reaching each milestone of success. NEXT is powered by Shulman Rogers, a full-service law firm with nearly 100 attorneys offering superior service across a wide range of practice areas. The firm also offers robust personal services such as residential closings and trust and estate planning. Shulman Rogers has earned its reputation for providing quality representation, business insight and client value, serving as a highly attractive alternative to larger, higher-priced firms and smaller, less diverse firms. Learn more at ShulmanRogers.com.

ANTHONY MILLIN, NEXT CHAIR & PARTNER, SHULMAN, ROGERS

Anthony Millin is the Chair of NEXT and a trusted legal and business advisor to startup, early-stage, and emerging growth companies. As a corporate and securities attorney, a successful serial entrepreneur, and a venture capitalist, Anthony brings a unique legal and business perspective to advising his clients. Anthony understands firsthand what it takes to start, scale and manage a company, to successfully prepare for and run a fund-raising process, and to address the legal issues faced by a startup. Another specialized skill set Anthony brings to the table is his China-based experience, assisting early-stage and middle-market companies interested in conducting business in China or seeking direct foreign investment from China. Anthony also serves as a Venture Partner at Urban Us, a seed-stage VC firm. Contact Anthony at amillin@shulmanrogers.com.

AEG @enterpriseGrowth

AEG is a "Time Machine" for business leaders. We accelerate development of trust, driving fast and efficient referrals to accelerate business development and growth. We are a values-based membership organization of three communities (1) CEOs of \$20M+ companies in diverse industries, (2) elite advisors in complementary disciplines, and (3) regional centers of influence including economic development, trade associations and media.

MARK HAAS, CEO, AEG @MarkHaas

Mark Haas is Co-founder and CEO of AEG (Association for Enterprise Growth), responsible for strategy, operations, and expansion of its communities to 30 cities nationally. He was previously President of ROM a strategy and operations management consulting firm, advising CEOs and boards to include leadership training for Tanzanian energy executives, developing curricula to train consultants in 40 countries for an international bank, crafting strategy and innovative business models for \$120 million nonprofit, merging two scientific associations, re-organizing a biomedical research agency, facilitating development of WWIV military strategy, and of facilitating a global R&D strategy for the US Navy.

PRINCE WILLIAM COUNTY DEPARTMENT OF ECONOMIC DEVELOPMENT

The Prince William County Department of Economic Development and Tourism works hard to create a pro-business, globally-competitive environment that generates new, high-quality, and sustainable job opportunities for our residents and destination-driven attractions for our visitors. The department engages in a broad portfolio of services, partnerships, and strategic alliances to benefit the business community, including small businesses, startups, and entrepreneurs.



PARTNERS



MICHELE WEATHERLY, DIRECTOR OF EXISTING BUSINESS AND ENTREPRENEURSHIP, PRINCE WILLIAM COUNTY

Michele Weatherly currently serves as the Director of Existing Business and Entrepreneurship with Prince William County Department of Economic Development and Tourism. Michele is a Washington DC Metro area Business Development professional with a track record of successful leadership in trade associations and economic development. Michele specializes in workforce and business development programs and marketing with a strong network of industry colleagues in the DC metro region and beyond the beltway.

Michele currently serves on the Board of Directors for Virginia Career Works, Committee for Dulles, Virginia Serious Game Institute, and the Career Technical Education Program Advisory Council for Prince William County Schools.



REFRACTION @refractionpt

Refraction is a leading nonprofit innovation hub in Northern Virginia, that provides mentoring, programs, and office space for startups and high-growth companies to help create jobs in the greater Washington region. In five years, more than 300 member companies have collectively raised over \$350 million in capital. Refraction's partners include Amazon, Cox, Dominion Energy, MITRE, Fairfax County, Arlington County, Loudoun County, Virginia Innovation Partnership Corporation, and Virginia Tech.



DINGMAN CENTER FOR ENTREPRENEURSHIP, UNIVERSITY OF MARYLAND @UMD_Dingman

The Dingman Center for Entrepreneurship is a top-tier entrepreneurial institute recognized around the world as a leader in enterprise creation. The Dingman Center is continuously pushing the boundaries of teaching and learning with its focus on practical entrepreneurship, global innovation, and international classroom experiences. The Center promotes opportunities that provide maximum resources to start-up businesses in terms of ideation, execution, and financing; and that support its mission to take entrepreneurs "from the back of a napkin to the first \$1 million in financing."



KEIRETSU FORUM @KeiretsuAngels

Keiretsu Forum is a global investment community of accredited private equity angel investors, venture capitalists, and corporate/institutional investors. Keiretsu Forum was founded in the San Francisco East Bay in California in 2000 by Randy Williams. Keiretsu Forum is a worldwide network of capital, resources, and deal flow with 53 chapters on 3 continents. Keiretsu Forum members invest in high-quality, diverse investment opportunities.



FITCI - FREDERICK INNOVATIVE TECHNOLOGY CENTER, INC @FITCInc

The Frederick Innovative Technology Center, Inc. (FITCI) is a business incubator and accelerator designed to cultivate entrepreneurship in Frederick, Maryland. FITCI specializes in the strategic business support of local entrepreneurs in the early stages of mostly science and technology-based businesses: Biotechnology, Information Technology, Renewable Energy, and Cyber Security. FITCI currently has two locations in Fredrick, MD, and 52 client companies.



THE BALTIMORE ANGELS @baltimoreangels

The Baltimore Angels is an angel investor group based in Baltimore, MD. Founded in 2009, its mission is to invest profitably in the regional entrepreneurial ecosystem and advance early-stage innovators to the next stage of capital formation. Its vision is to be the most trusted resource for angel capital investment and entrepreneurial mentorship in the Greater Baltimore region. A new generation of angel investing comes to Baltimore. If you are a tech entrepreneur or community-minded investor, please be in touch with Baltimore Angels. This is not your father's (or your uncle's) investment group.

PARTNERS



MARYLAND TECH COUNCIL VENTURE MENTORING SERVICES

The Maryland Tech Council Venture Mentoring Services (MTC VMS) program is one of the leading team mentoring services available in the state of Maryland that is both highly sophisticated and results-driven. It exists to foster an environment that encourages innovation while expanding financial and business opportunities for tech, cyber, and life science start-ups. The MTC VMS Program provides free team-based mentoring services to qualified Maryland-based tech and life science venture CEOs who are accepted into the program. Since the MTC VMS program began, more than 75 ventures have enrolled & \$100MM has been raised in capital & grants.



STARTUP GRIND-COLUMBIA, MD eStartupGrindDC

Startup Grind-Columbia, mid-Maryland Chapter is part of the largest global community for innovation, entrepreneurship, and the startup community. We're actively educating, inspiring, and connecting more than 2MM+entrepreneurs, 600+ cities, and 130+ countries. We nurture startup ecosystems through mentorship, advisory services, education, inspiration, access to capital, and most importantly, connecting members with the resources we need to have the best opportunity to grow phenomenally successful ventures.



ANGELS + LIFE.SCI INVESTORS

Formed in 1996, the Angels + Life.Sci Investors Network is organized under NJAngels.net. We are a manager-led, loosely organized network of investors and accredited Angels, Coaches, and Experts who Sponsor world-class Entrepreneurs. Our colleagues have deep experience and technical domain expertise in all of the life sciences disciplines in which we are involved, including nanobio tools, materials, and devices: tele-diagnostics, augmented healthcare & remote patient monitoring, automation and robotics, & advanced chemistry for drug discovery.



GEORGETOWN ENTREPRENEURSHIP INITIATIVE

Entrepreneurship is one of the world's most powerful forces for positive change. Georgetown Entrepreneurship seeks to instill an entrepreneurial mindset in students, foster an entrepreneurial culture across the university, support the successful growth of alumni ventures, and leverage the power of entrepreneurship to make an impact in the world beyond Georgetown.



JEFF REID, FOUNDING DIRECTOR, GEORGETOWN ENTREPRENEURSHIP INITIATIVE, GEORGETOWN UNIVERSITY'S MCDONOUGH SCHOOL OF BUSINESS eHoyapreneur

Jeff Reid is the Founding Director of the Georgetown Entrepreneurship Initiative and Professor of the Practice of Entrepreneurship at Georgetown University's McDonough School of Business. Reid is a catalyst for entrepreneurship and a well-known leader in entrepreneurship education. In 2009, Reid launched the Georgetown Entrepreneurship Initiative to catalyze entrepreneurial thinking and activities across Georgetown University and impact the growing DMV startup community.



RYAN & WETMORE, P.C. eRyanWetmorePC

Ryan & Wetmore is a full-service accounting and management consulting firm, servicing the Northeast/ Mid-Atlantic region since 1988. What makes us different from other accounting firms is our proactive approach. We work hard to earn our clients' confidence by encouraging open communication year-round. This approach has enabled us to help clients become more efficient, more competitive, and more profitable. Through our numerous management engagements, we have become trusted, unbiased advisors.

PARTNERS



PETE RYAN, CO-FOUNDER & PARTNER, RYAN & WETMORE

Pete co-founded Ryan & Wetmore in 1988, a 3 office, 35-person firm serving the Mid-Atlantic region. He currently works with clients to address tax, audit, and accounting issues. He also has significant experience in international tax matters and business consulting services. His expertise extends to Healthcare organizations, Construction and Real Estate, Government contractors, Technology, Manufacturing, and High Net Worth Individuals. Pete has served on the Board of Directors for several organizations. He is an active member of the Healthcare Advisors Association, the Real Estate and Construction Association, the CPA Manufacturing Services Association, the Virginia Transportation Construction Alliance, and the Construction Financial Management Association.



ENTERPRISE TRANSFORMATION SOLUTIONS

INES LEBOW, FOUNDER AND PRINCIPAL @ilebow1

Ines LeBow is the Founder and Principal Startup Consultant at Enterprise Transformation Solutions (ETS), which advises entrepreneurs on how to position themselves for funding. Over the course of her 30+ years in the industry, Ines has helped companies secure more than \$800M in funding, led start-ups and turnarounds for companies with up to \$500M in revenue, managed 11 M&A transactions, and guided 9 companies to a successful exit. With expertise spanning Operations, Executive Leadership, and Mentoring, Turnarounds, Revenue implementation, Engineering, as well as Communications, Ines has helped many companies prepare for VC and angel investment.



THANK YOU TO OUR PREP TEAM



LAURA HILL
SVP
Equifi



INES LEBOW
CEO
Enterprise Transformation
Solutions



MARISSA LEVIN
CEO
Successful Culture
International



BOB LONDON
CEO
Chief Listening Officers



JET LU
Customer Solutions
Amazon Web Services



JACKIE LUO
Founder
BAM Advisory



MICHELLE MILLER
Founder
MRM Consulting



JOHN MORGAN
General Partner
Morgan Global



EVAN SHUBIN
Pres. and Founder
Results.now, Inc. and
Candlelight Partners



MALI PHONPADITH
CEO
SOAR Community
Network



MICHAEL RIEMER
CEO & Board Member
Vocinity

SPONSORS



Angels + Life.Sci Investors



WANT TO PRESENT OR SPONSOR AT OUR VIRTUAL EVENTS?

**Email Skylar Rallison at
srallison@opus8.com
for more information**

2024 Virtual Calendar

Aug. 29

Oct. 31

Nov. 21

Dec. 19

REGISTER FOR OUR UPCOMING EVENTS

August 8
In-Person



August 29
Virtual Pitch



September 19
In-Person



CONNECT WITH US!





CUSTOM PRIVATE INVESTOR MEETING

Overview

- Opus8 manages one of the world's largest investor communities with 4,000+ HNW/UHNW private investors, angels, family offices, investment groups, and small institutional investors.
- We have become a reliable curator and source of high-quality investment opportunities for this community.
- The Client is the exclusive host of these private investor meetings. No other competing or external entities in the meeting.
- Opus8 will screen a minimum of 20+ pre-qualified attendees for the event. The general attendee mix is 75% investors and 25% COIs (Centers of Influence).
- Attendee/RSVP lists with contact information and LinkedIn profiles and other data will be provided to the Client before and after the event.

Our 9-Step Process

1. Review investment materials and determine key investment considerations.
2. Develop a list of potential investors.
3. Create a "teaser invitation" and send it to investor candidates along with an executive summary
4. Confirm and vet RSVPs
5. Answer any questions or info requests pre-event.
6. Triple confirm all RSVPs via email and calendar invitations.
7. Host the private investor event and follow-up with attendees.
8. Introduce any RSVPs who did not attend to management.
9. Assist in following up with any and all investor prospects post-event.

Check out the full brochure with all information here:

